Dec 22, 2020, 08:30
Carbiotix (publ) ("Carbiotix") announces today that the company has signed three LinkGut API partner agreements in Q4 2020. These partners include one start-up company in Europe and two in North America. LinkGut API partners utilise Carbiotix consumer gut health test as their primary analytical service to generate customer microbiome data. This is a significant step for Carbiotix as API partners will become Carbiotix’s primary driver of diagnostic service sales from Q2 2021 onwards. The financial value of the agreements for the LinkGut service cannot be determined as it is the customers of the partners who pay for the service. The agreements run indefinitely.
Carbiotix's API (application programming interface) partners include one start-up company in Europe focused on microbiome health, bioinformatics, and prebiotics, and two companies in North America targeting GI-related medical advice and infant gut health respectively. As always, the names of the API partners are publicly disclosed at their discretion. LinkGut (https://carbiotix.com/linkgut) is a white label testing service for gut health offered to food & beverage, supplement, pharmaceutical, and health & wellness companies. The service is offered as a no-cost, dedicated, and customised website extension allowing a company to offer their own consumer gut health test, or as an API solution that is completely integrated into the backend of another APP or web service. In both cases, the service is based on Carbiotix’s OneGut platform, a cost-effective and reliable consumer gut health test.
Kristofer Cook, CEO for Carbiotix, comments
"As I have previously communicated, Carbiotix will announce new LinkGut partners quarterly going forward unless we believe the partner may be of special interest for the market. It is my ambition to aggressively grow our LinkGut partner network going forward, especially API partners. I am extremely pleased to have signed these three agreements as it demonstrates the appeal of our service offering and has accelerated the development of our API solution which we should have in place by the end of Q1 2021. This means that from Q2 onwards we will be able to quickly roll out an API solution to all companies planning to offer a consumer microbiome analysis service, or interested to bring down the cost and/or outsource an existing service. Although LinkGut partners such as food & beverage companies who utilise our website extension solution are potential customers of our AXOS ingredient, they will not be the primary drivers of diagnostic service sales. This is because our gut health test is offered as an "extra service" to their customers to embrace transparency and validate the effects of a gut health-related product over time. On the other hand, API partners will utilise the Carbiotix OneGut platform as their primary analytical service to deliver a gut health-related service. Thus, as these companies grow their customer base and geographic presence, so will the number of gut health tests we sell.
With this development, Carbiotix has once again disrupted the consumer microbiome service industry. There is now no logical reason why an existing or new company interested in collecting consumer related microbiome data would build their platform and not utilise the Carbiotix OneGut solution. We are the only company in the world to offer a triplicate test for both NGS and PCR analysis, and thus are more reliable, our cost is the same as the lowest competitive price on the market including courier shipping to and from customers in over 200 countries and thus support global roll-out, and we intend to continuously lower our prices over time as our modulator sales grow with the purpose of maintaining our competitive advantage. For us, our OneGut service is a means to build relationships with AXOS customers as well as their customers (ie. consumers), in addition to potential partners and advocates of all the modulators we will offer, including ingredients, medical foods, and therapeutic interventions."
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 (0)708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.Go Back